Macrogenics Inc MGNX
Macrogenics Inc (Nasdaq: MGNX) is an oncology drug developer. Its lead program, MGC026 (B7-H3 TOP1i ADC) / MGC028 (ADAM9 TOP1i ADC), is in Phase 1 for advanced solid tumors. Its next catalyst on record is MGC028: Initial clinical data report (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: MGC028 — Initial clinical data report (H2 2026). 7 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| vobramitamab duocarmazine | discontinued internal development | antibody | Phase 2 |
| MGC026 | B7-H3-expressing solid tumors (Phase 1 dose escalation fully enrolled; dose expansion ongoing) | antibody | Phase 1 |
| MGC028 | advanced solid tumors (ADAM9) | antibody | Phase 1 |
| lorigerlimab (PD-1 x CTLA-4 DART) | not stated in extract (LORIKEET and LINNET studies referenced) | antibody | Phase 1 |
| MGD024 (CD123 x CD3 DART, Gilead option) | hematologic malignancies (CD123) | antibody | Phase 1 |
| MGC030 (ADC, undisclosed target) | solid tumors | antibody | Pre-clinical |
Recent results and decisions
- Oct 23, 2026positive MGC026 demonstrated durable responses with 29% confirmed ORR in patients with advanced solid tumors receiving ≥6 mg/kg dose.
Among 17 response-evaluable patients representing 10 different tumor types who received MGC026 at doses of at least 6 mg/kg in dose escalation, the confirmed objective response rate was 29% (5/17), and the disease control rate was 65% (11/17).
Filing - Oct 23, 2026n/a MacroGenics plans to initiate an expansion cohort in early 2027 evaluating MGC026 in combination with pembrolizumab in front-line SCCHN patients with PD-L1 positive disease.
The Company plans to initiate an expansion cohort in early 2027 evaluating MGC026 in combination with pembrolizumab in front-line patients with PD-L1 positive (CPS ≥1) recurrent or metastatic SCCHN.
Filing - Oct 23, 2026n/a Company plans to initiate front-line SCCHN expansion cohort evaluating MGC026 in combination with pembrolizumab in early 2027.
The Company plans to initiate an expansion cohort in early 2027 evaluating MGC026 in combination with pembrolizumab in front-line patients with PD-L1 positive (CPS ≥1) recurrent or metastatic SCCHN.
Filing
5 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
- Erasca, Inc. ERAS
- Parabilis Medicines, Inc. PBLS
- Xencor Inc XNCR
- Schrodinger, Inc. SDGR
- Vir Biotechnology, Inc. VIR
- Zymeworks Inc. ZYME
- Janux Therapeutics, Inc. JANX
- Aktis Oncology, Inc. AKTS
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.